{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:23Z","timestamp":1792788563346,"version":"4.5.0"},"reference-count":101,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Safety Platform for Emergency Vaccines"},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lassa fever (LF) is an acute viral hemorrhagic illness endemic in West Africa, representing significant public health challenges, particularly for pregnant persons and children who experience higher morbidity and mortality. Although several vaccine candidates are being developed, no LF vaccine has been licensed yet.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a living systematic review (LSR) of the literature to evaluate the safety, efficacy, effectiveness, and immunogenicity of LF vaccines. We performed biweekly searches in major biomedical databases, trial registries, preprint servers, and other sources. Eligible studies included preclinical studies, clinical trials, and observational studies published from January 2014 to April 2025. Reviewer pairs screened studies extracted data (REDCap), and assessed risk of bias independently. Data synthesis involved random-effects pairwise and proportion meta-analyses (R software), with GRADE assessment of evidence certainty. PROSPERO registries: (CRD42024514513; CRD42024516754).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Searches retrieved 1423 records, including 51 studies, 2 clinical trials in adults involving 88 vaccinated persons, and 49 preclinical studies of 30 vaccine candidates. Trials evaluated Recombinant Measles-Vectored (MV-LASV) and Recombinant Vesicular Stomatitis Virus-based (rVSV\u0394G-LASV-GPC) LF vaccine candidates. No published clinical trials were found to evaluate LF vaccines in special populations such as pregnant persons, infants, children, or adolescents. Although injection site reactogenicity was reported, no vaccine-related serious adverse events (SAEs) were reported in study participants. Immunogenicity was robust in adults, with vaccines achieving around 95% seroconversion at 30 days. Preclinical data evaluated nine different platforms. Findings are disseminated via an interactive online dashboard (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/safeinpregnancy.org\/living-systematic-review-lassa\/\" xlink:type=\"simple\">https:\/\/safeinpregnancy.org\/living-systematic-review-lassa\/<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Currently, two LF vaccine candidates that have advanced to clinical trials exhibit high immunogenicity, but the safety profile in healthy adults is still limited. Clinical evidence in pregnant persons, infants, children, and adolescents is absent. Vaccine platforms of interest have been identified in preclinical studies, providing information on those that could advance to clinical studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0338128","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:29:46Z","timestamp":1765996186000},"page":"e0338128","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy, safety, and immunogenicity of Lassa fever vaccines: A living systematic review and landscape analysis of vaccine candidates"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4437-0073","authenticated-orcid":true,"given":"Ariel","family":"Bardach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Berrueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Ciapponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6277-2469","authenticated-orcid":true,"given":"Juan M.","family":"Sambade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Castellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8040","authenticated-orcid":true,"given":"Jamile","family":"Ballivian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2113-449X","authenticated-orcid":true,"given":"Mart\u00edn","family":"Brizuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta","family":"Caravario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7111-5169","authenticated-orcid":true,"given":"Daniel","family":"Comande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Mazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P. K.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"Salva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Stegelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Schieffelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Stergachis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flor M.","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Buekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"15","key":"pone.0338128.ref001","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1128\/JVI.74.15.6992-7004.2000","article-title":"Genetic diversity among Lassa virus strains","volume":"74","author":"MD Bowen","year":"2000","journal-title":"J Virol"},{"issue":"7426","key":"pone.0338128.ref002","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.327.7426.1271","article-title":"Lassa fever: epidemiology, clinical features, and social consequences","volume":"327","author":"JK Richmond","year":"2003","journal-title":"BMJ"},{"key":"pone.0338128.ref003","unstructured":"WHO. Lassa fever [Internet]. 2025 [cited 2025 Oct 13]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lassa-fever"},{"issue":"6","key":"pone.0338128.ref004","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3201\/eid2506.181035","article-title":"Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1-May 6, 2018","volume":"25","author":"EA Ilori","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"pone.0338128.ref005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamapediatrics.2017.5223","article-title":"What Pediatricians Should Know About Lassa Virus","volume":"172","author":"D Greenky","year":"2018","journal-title":"JAMA Pediatr"},{"key":"pone.0338128.ref006","unstructured":"CDC. Lassa Fever. 2025 [cited 2025 Oct 13]. About. Available from: https:\/\/www.cdc.gov\/vhf\/lassa\/index.html"},{"issue":"5","key":"pone.0338128.ref007","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/inthealth\/ihac076","article-title":"Lassa fever cases suffer from severe underreporting based on reported fatalities","volume":"15","author":"D Simons","year":"2023","journal-title":"Int Health"},{"key":"pone.0338128.ref008","unstructured":"[cited 2025 Oct 13]. Available from: https:\/\/www.cdc.gov\/vhf\/lassa\/symptoms\/index.html"},{"key":"pone.0338128.ref009","unstructured":"Nigeria Centre for Disease Control and Prevention. An update of Lassa fever outbreak in Nigeria. NCDC Situation Report."},{"issue":"4","key":"pone.0338128.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(20)30518-0","article-title":"Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study","volume":"9","author":"A Duvignaud","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"6648","key":"pone.0338128.ref011","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/bmj.297.6648.584","article-title":"A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy","volume":"297","author":"ME Price","year":"1988","journal-title":"BMJ"},{"issue":"8","key":"pone.0338128.ref012","doi-asserted-by":"crossref","DOI":"10.3201\/eid2508.181299","article-title":"Retrospective cohort study of Lassa fever in pregnancy, southern Nigeria","volume":"25","author":"S Okogbenin","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"pone.0338128.ref013","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/archdischild-2014-307861","article-title":"Viral haemorrhagic fever in children","volume":"101","author":"NE MacDermott","year":"2016","journal-title":"Arch Dis Child"},{"issue":"3","key":"pone.0338128.ref014","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ni0311-189","article-title":"Challenges in infant immunity: implications for responses to infection and vaccines","volume":"12","author":"M PrabhuDas","year":"2011","journal-title":"Nat Immunol"},{"issue":"2","key":"pone.0338128.ref015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006187","article-title":"Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden","volume":"12","author":"EJ Mateer","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pone.0338128.ref016","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/tmi.13876","article-title":"Lassa fever vaccine candidates: A scoping review of vaccine clinical trials","volume":"28","author":"G Sulis","year":"2023","journal-title":"Trop Med Int Health"},{"issue":"4","key":"pone.0338128.ref017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003212","article-title":"Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials","volume":"9","author":"S Olschl\u00e4ger","year":"2013","journal-title":"PLoS Pathog"},{"key":"pone.0338128.ref018","doi-asserted-by":"crossref","first-page":"46","DOI":"10.21010\/Ajidv16i2S.6","article-title":"Prospects of Lassa fever candidate vaccines.","volume":"16","author":"Babatunde Ademusire","year":"2022","journal-title":"Afr J Infect Dis"},{"key":"pone.0338128.ref019","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000004565","volume":"44","author":"M Berrueta","year":"2025","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"pone.0338128.ref020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12978-025-02090-2","article-title":"A global living systematic review and meta-analysis hub of emerging vaccines in pregnancy and childhood","volume":"22","author":"A Ciapponi","year":"2025","journal-title":"Reprod Health"},{"key":"pone.0338128.ref021","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPT Higgins","year":"2019"},{"issue":"3","key":"pone.0338128.ref022","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"18","author":"MJ Page","year":"2021","journal-title":"PLoS Med"},{"key":"pone.0338128.ref023","doi-asserted-by":"crossref","first-page":"192","DOI":"10.12688\/f1000research.51723.3","article-title":"Tailored PRISMA 2020 flow diagrams for living systematic reviews: a methodological survey and a proposal","volume":"10","author":"LA Kahale","year":"2021","journal-title":"F1000Res"},{"issue":"1","key":"pone.0338128.ref024","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12978-025-02008-y","article-title":"Safety, immunogenicity, efficacy, and effectiveness of Lassa fever vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis","volume":"22","author":"J Ballivian","year":"2025","journal-title":"Reprod Health"},{"issue":"49","key":"pone.0338128.ref025","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1016\/j.vaccine.2016.07.006","article-title":"Global alignment of immunization safety assessment in pregnancy - The GAIA project","volume":"34","author":"J Bonhoeffer","year":"2016","journal-title":"Vaccine"},{"key":"pone.0338128.ref026","unstructured":"SPEAC - [Internet]. SPEAC; 2023 [cited 2025 Oct 13]. Lassa Fever - SPEAC. Available from: https:\/\/speacsafety.net\/tools\/aesi-lists\/lassa-fever\/"},{"key":"pone.0338128.ref027","unstructured":"World Health Organization. Lassa Fever Outbreak Toolbox [Internet]. [cited 2025 Oct 13]. Available from: https:\/\/www.who.int\/emergencies\/outbreak-toolkit\/disease-outbreak-toolboxes\/lassa-fever-outbreak-toolbox"},{"issue":"2","key":"pone.0338128.ref028","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"PA Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"pone.0338128.ref029","unstructured":"[cited 2025 Oct 13]. Available from: https:\/\/methods.cochrane"},{"key":"pone.0338128.ref030","unstructured":"[cited 2025 Oct 13]. Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quali"},{"key":"pone.0338128.ref031","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604.ch14","article-title":"Completing \u201csummary of findings\u201d tables and grading the certainty of the evidence.","volume-title":"Cochrane","author":"G Sch\u00fcnemann","year":"2019"},{"key":"pone.0338128.ref032","unstructured":"The R Project for Statistical Computing [Internet]. [cited 2025 Oct 13]. Available from: https:\/\/www.r-project.org\/"},{"key":"pone.0338128.ref033","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6","author":"JJ Deeks"},{"key":"pone.0338128.ref034","article-title":"First safety & immunogenicity data from a first-in-human, placebo-controlled, dose-escalation trial of a recombinant vesicular stomatitis virus-based Lassa fever vaccine in healthy adults.","volume-title":"Poster presented at the Annual Meeting of the","author":"E Malkin","year":"2023"},{"key":"pone.0338128.ref035","unstructured":"Participants in Nigeria vaccinated in first-ever Phase 2 Lassa fever vaccine clinical trial, sponsored by. IAVI [Internet] International AIDS Vaccine Initiative. 2024."},{"issue":"10384","key":"pone.0338128.ref036","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(23)00048-X","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial","volume":"401","author":"R Tschismarov","year":"2023","journal-title":"Lancet"},{"key":"pone.0338128.ref037","unstructured":"Malkin E, Baden L, Kieh M, Fitz-Patrick D, Diemert D, Mutua G, et al. First safety & immunogenicity data from a first-in-human, placebo-controlled, dose-escalation trial of a recombinant vesicular stomatitis virus-based Lassa fever vaccine in healthy adults. Poster presented at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH); 2023 Oct; Chicago, IL, USA [Internet]. [cited 2024 Dec 29]. Available from: https:\/\/www.iavi.org\/wp-content\/uploads\/2023\/11\/c102_astmh_poster_chicago2023.pdf"},{"key":"pone.0338128.ref038","unstructured":"ClinicalTrials.gov [Internet]. [cited 2025 Oct 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05868733"},{"key":"pone.0338128.ref039","unstructured":"IAVI [Internet]. International AIDS Vaccine Initiative; 2024 [cited 2025 Oct 13]. Participants in Nigeria vaccinated in first-ever Phase 2 Lassa fever vaccine clinical trial, sponsored by. Available from: https:\/\/www.iavi.org\/press-release\/iavi-c105-lassa-fever-vaccine-clinical-trial\/"},{"key":"pone.0338128.ref040","unstructured":"Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate."},{"key":"pone.0338128.ref041","unstructured":"INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa [Internet]. [cited 2025 Oct 13]. Available from: https:\/\/ir.inovio.com\/news-releases\/news-releases-details\/2021\/INOVIO-Completes-Enrollment-of-Phase-1B-Clinical-Trial-for-its-DNA-Vaccine-Candidate-Against-Lassa-Fever-INO-4500-in-West-Africa\/default.aspx"},{"key":"pone.0338128.ref042","unstructured":"ClinicalTrials.gov [Internet]. [cited 2025 Oct 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06546709?cond=NCT06546709%20&rank=1"},{"key":"pone.0338128.ref043","doi-asserted-by":"crossref","unstructured":"Quintero Barceinas RS. VITAL01: A study of a new vaccine against Lassa fever in adults aged 18-55 years [Internet]. http:\/\/isrctn.com\/. Springer Science and Business Media LLC; 2025. Available from: http:\/\/dx.doi.org\/10.1186\/isrctn16084957","DOI":"10.1186\/ISRCTN16084957"},{"key":"pone.0338128.ref044","unstructured":"ClinicalTrials.gov [Internet]. [cited 2025 Oct 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05868733?cond=Lassa%20Fever&term=children&intr=vaccine&rank=1"},{"key":"pone.0338128.ref045","unstructured":"ClinicalTrials.gov [Internet]. [cited 2025 Oct 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06546709?cond=NCT06546709&rank=1"},{"key":"pone.0338128.ref046","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2147\/DDDT.S147276","article-title":"Current research for a vaccine against Lassa hemorrhagic fever virus","volume":"12","author":"BM Warner","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"pone.0338128.ref047","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/v13030382","article-title":"Multivalent DNA Vaccines as A Strategy to Combat Multiple Concurrent Epidemics: Mosquito-Borne and Hemorrhagic Fever Viruses","volume":"13","author":"J Jiang","year":"2021","journal-title":"Viruses"},{"issue":"9","key":"pone.0338128.ref048","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1080\/21645515.2019.1616499","article-title":"Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques","volume":"15","author":"J Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"pone.0338128.ref049","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41541-024-00930-z","article-title":"Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease","volume":"9","author":"G Scher","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"1","key":"pone.0338128.ref050","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"T Abreu-Mota","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0338128.ref051","article-title":"A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene","volume":"11","author":"Y Cai","year":"2020","journal-title":"mBio"},{"issue":"1","key":"pone.0338128.ref052","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41541-024-01012-w","article-title":"A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs","volume":"9","author":"BD Carey","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"2","key":"pone.0338128.ref053","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/v13020214","article-title":"Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and Attenuation","volume":"13","author":"DM Johnson","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"pone.0338128.ref054","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/pathogens8010009","article-title":"Attenuated Replication of Lassa Virus Vaccine Candidate ML29 in STAT-1-\/- Mice","volume":"8","author":"DM Johnson","year":"2019","journal-title":"Pathogens"},{"issue":"6","key":"pone.0338128.ref055","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1128\/JVI.03035-13","article-title":"Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate","volume":"88","author":"JC Zapata","year":"2014","journal-title":"J Virol"},{"issue":"2","key":"pone.0338128.ref056","article-title":"A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region","volume":"11","author":"Y Cai","year":"2020","journal-title":"mBio"},{"issue":"1","key":"pone.0338128.ref057","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41541-025-01090-4","article-title":"Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV","volume":"10","author":"S Wang","year":"2025","journal-title":"NPJ Vaccines"},{"issue":"1","key":"pone.0338128.ref058","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41467-023-44534-y","article-title":"Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability","volume":"15","author":"J Gorman","year":"2024","journal-title":"Nat Commun"},{"key":"pone.0338128.ref059","doi-asserted-by":"crossref","first-page":"963023","DOI":"10.3389\/fimmu.2022.963023","article-title":"A platform technology for generating subunit vaccines against diverse viral pathogens","volume":"13","author":"A Young","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"pone.0338128.ref060","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.4161\/hv.34413","article-title":"VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever","volume":"10","author":"P Leblanc","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"pone.0338128.ref061","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41541-020-00219-x","article-title":"Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity","volume":"5","author":"H M\u00fcller","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"8","key":"pone.0338128.ref062","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/infdis\/jiz284","article-title":"Protection from lethal Lassa disease can be achieved both before and after virus exposure by administration of single-cycle replicating Lassa virus replicon particles","volume":"220","author":"MH Kainulainen","year":"2019","journal-title":"J Infect Dis"},{"key":"pone.0338128.ref063","doi-asserted-by":"crossref","first-page":"105647","DOI":"10.1016\/j.ebiom.2025.105647","article-title":"Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials","volume":"114","author":"CL Cooper","year":"2025","journal-title":"EBioMedicine"},{"issue":"3","key":"pone.0338128.ref064","doi-asserted-by":"crossref","first-page":"111094","DOI":"10.1016\/j.celrep.2022.111094","article-title":"A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever","volume":"40","author":"RW Cross","year":"2022","journal-title":"Cell Rep"},{"key":"pone.0338128.ref065","doi-asserted-by":"crossref","first-page":"847598","DOI":"10.3389\/fitd.2022.847598","article-title":"Adjuvants Differentially Modulate the Immunogenicity of Lassa Virus Glycoprotein Subunits in Mice","volume":"3","author":"A To","year":"2022","journal-title":"Front Trop Dis"},{"issue":"1","key":"pone.0338128.ref066","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI131958","article-title":"Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death","volume":"130","author":"RW Cross","year":"2020","journal-title":"J Clin Invest"},{"key":"pone.0338128.ref067","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41541-019-0104-x","article-title":"A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs","volume":"4","author":"DR Stein","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"2","key":"pone.0338128.ref068","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3201\/eid2102.141649","article-title":"Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses","volume":"21","author":"A Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"pone.0338128.ref069","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003736","article-title":"A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses","volume":"9","author":"D Safronetz","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pone.0338128.ref070","doi-asserted-by":"crossref","first-page":"153","DOI":"10.15789\/1563-0625-SOT-2988","article-title":"Study of the immunological efficacy and safety of a candidate vaccine against Lassa hemorrhagic fever","volume":"27","author":"O Popova","year":"2025","journal-title":"Med Immunol"},{"issue":"1","key":"pone.0338128.ref071","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41541-021-00291-x","article-title":"ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge","volume":"6","author":"RJ Fischer","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"6","key":"pone.0338128.ref072","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012262","article-title":"Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse","volume":"20","author":"A Flaxman","year":"2024","journal-title":"PLoS Pathog"},{"issue":"3","key":"pone.0338128.ref073","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/v13030484","article-title":"Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever","volume":"13","author":"M Wang","year":"2021","journal-title":"Viruses"},{"issue":"6","key":"pone.0338128.ref074","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/infdis\/jiab014","article-title":"Tetravalent rabies-vectored filovirus and Lassa fever vaccine induces long-term immunity in nonhuman primates","volume":"224","author":"D Kurup","year":"2021","journal-title":"J Infect Dis"},{"issue":"45","key":"pone.0338128.ref075","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1016\/j.vaccine.2019.09.030","article-title":"Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs","volume":"37","author":"J Maruyama","year":"2019","journal-title":"Vaccine"},{"issue":"36","key":"pone.0338128.ref076","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1016\/j.vaccine.2019.07.023","article-title":"A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model","volume":"37","author":"EM Kennedy","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"pone.0338128.ref077","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/pathogens8030133","article-title":"A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge","volume":"8","author":"MS Salvato","year":"2019","journal-title":"Pathogens"},{"issue":"1","key":"pone.0338128.ref078","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.qai.0000532509.06857.35","article-title":"P-C3 A Modified Vaccinia Ankara vector expressing Lassa virus-like particles (MVA-LasVLP) protects mice from lethal challenge with a Lassa-Mopeia reassortant virus","volume":"77","author":"MC Guzman","year":"2018","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"issue":"12","key":"pone.0338128.ref079","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/infdis\/jiy123","article-title":"Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model","volume":"217","author":"MH Kainulainen","year":"2018","journal-title":"J Infect Dis"},{"issue":"6","key":"pone.0338128.ref080","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00578-24","article-title":"An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice","volume":"98","author":"M Hashizume","year":"2024","journal-title":"J Virol"},{"issue":"1","key":"pone.0338128.ref081","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1038\/s41467-023-41376-6","article-title":"A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection","volume":"14","author":"AJ Ronk","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0338128.ref082","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s43856-024-00684-8","article-title":"The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa fever","volume":"4","author":"VM Andrade","year":"2024","journal-title":"Commun Med (Lond)"},{"issue":"12","key":"pone.0338128.ref083","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1080\/21645515.2017.1382780","article-title":"DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs","volume":"13","author":"KA Cashman","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"pone.0338128.ref084","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1080\/21645515.2017.1356500","article-title":"A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever","volume":"13","author":"KA Cashman","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"38","key":"pone.0338128.ref085","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1016\/j.vaccine.2017.07.101","article-title":"An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions","volume":"35","author":"Q Li","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"pone.0338128.ref086","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/futurepharmacol5020026","article-title":"Safety Toxicology Study of Reassortant Mopeia-Lassa Vaccine in Guinea Pigs","volume":"5","author":"BS Wahle","year":"2025","journal-title":"Future Pharmacol"},{"key":"pone.0338128.ref087","unstructured":"\u0421\u0442\u0430\u0442\u044c\u044e \u041e. \u041c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0430\u044f \u0438\u043c\u043c\u0443\u043d\u043e\u043b\u043e\u0433\u0438\u044f [Internet]. [cited 2025 Oct 13]. Available from: https:\/\/www.mimmun.ru\/mimmun\/index"},{"issue":"8","key":"pone.0338128.ref088","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/vaccines12080858","article-title":"Preclinical Safety Assessment of the EBS-LASV Vaccine Candidate against Lassa Fever Virus","volume":"12","author":"D Matassov","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"pone.0338128.ref089","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/s41467-023-37050-6","article-title":"Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys","volume":"14","author":"M Mateo","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"pone.0338128.ref090","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jat.4421","article-title":"Biodistribution and toxicology evaluation of a recombinant measles Schwarz-based Lassa vaccine in cynomolgus macaques","volume":"43","author":"S Schrauf","year":"2023","journal-title":"J Appl Toxicol"},{"issue":"597","key":"pone.0338128.ref091","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf6348","article-title":"A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains","volume":"13","author":"M Mateo","year":"2021","journal-title":"Sci Transl Med"},{"issue":"512","key":"pone.0338128.ref092","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw3163","article-title":"Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot","volume":"11","author":"M Mateo","year":"2019","journal-title":"Sci Transl Med"},{"key":"pone.0338128.ref093","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijid.2018.11.034","article-title":"One-shot immunization using a measles\/lassa vaccine fully protects cynomolgus monkeys against lassa fever","volume":"79","author":"M Mateo","year":"2019","journal-title":"Int J Infect Dis"},{"key":"pone.0338128.ref094","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.virol.2017.09.013","article-title":"Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein","volume":"512","author":"C Galan-Navarro","year":"2017","journal-title":"Virology"},{"issue":"9","key":"pone.0338128.ref095","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/jiac028","article-title":"Lassa virus replicon particle vaccine protects strain 13\/N guinea pigs against challenge with geographically and genetically diverse viral strains","volume":"226","author":"JR Spengler","year":"2022","journal-title":"J Infect Dis"},{"issue":"5","key":"pone.0338128.ref096","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.vaccine.2017.12.046","article-title":"Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins","volume":"36","author":"M Wang","year":"2018","journal-title":"Vaccine"},{"key":"pone.0338128.ref097","first-page":"111","article-title":"Lassa Virus Countermeasures","volume":"440","author":"LI Melnik","year":"2023","journal-title":"Curr Top Microbiol Immunol"},{"key":"pone.0338128.ref098","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jclinepi.2017.08.010","article-title":"Living systematic review: 1. Introduction-the why, what, when, and how","volume":"91","author":"JH Elliott","year":"2017","journal-title":"J Clin Epidemiol"},{"issue":"51","key":"pone.0338128.ref099","doi-asserted-by":"crossref","first-page":"7357","DOI":"10.1016\/j.vaccine.2021.10.048","article-title":"Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women","volume":"39","author":"G Voss","year":"2021","journal-title":"Vaccine"},{"issue":"2","key":"pone.0338128.ref100","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3201\/eid2502.180836","article-title":"Lassa fever in travelers from West Africa, 1969-2016","volume":"25","author":"A Kofman","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"pone.0338128.ref101","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/cid\/cix406","article-title":"Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever","volume":"65","author":"VN Raabe","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:30:00Z","timestamp":1765996200000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338128"}},"subtitle":[],"editor":[{"given":"Osamudiamen Cyril","family":"Obasuyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":101,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0338128","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}